Eflapegrastim: Phase III started

Spectrum began the open-label, North American Phase III ADVANCE trial to compare subcutaneous eflapegrastim on day 2 of each 21-day cycle vs. Neulasta pegfilgrastim for 4 cycles in about 580 early st...